Antihypertensive Medications
dc.contributor.advisor | Utidjian, Levon |
dc.contributor.author | Utidjian, Levon |
dc.contributor.other | Children's Hospital of Philadelphia |
dc.date.accessioned | 2024-06-10T19:03:14Z |
dc.date.available | 2024-06-10T19:03:14Z |
dc.date.created | 2021-03-01 |
dc.description | This medication concept set includes the following ingredients: ambrisentan, bethanidine, bosentan, cadralazine, clonidine, debrisoquin, deserpidine, diazoxide, dihydralazine, doxazosin, guanethidine, Guanoxan, hydralazine, indoramin, ketanserin, macitentan, mecamylamine, methoserpidine, methyldopa, metyrosine, minoxidil, moxonidine, nitroprusside, pargyline, pinacidil, prazosin, Rauwolfia preparation, rescinnamine, reserpine, rilmenidine, riociguat, Sitaxentan, tadalafil, Trimazosin, trimethaphan, urapidil, veratrum. It also includes combinations of these ingredients with other antihypertensive medications. This code list was generated by taking the descendants of all the 'other' antihypertensive ingredients of interest, and also doing string matching on the concept_name of the ingredient. This broad concept set was intended to identify patients who received 'other' antihypertensive ingredient not listed as RAAS blockers, calcium channel blockers, beta-blockers, or diuretics. Limited to RxNorm and RxNorm Extension codes. Technical Note: This concept set was created when ingredients were required for some sites. It could be enhanced by using SCDF drug levels and taking descendants, which would also make this easier to refresh. |
dc.description.abstract | Concept set intended to identify patients with an exposure to an antihypertensive medication. |
dc.identifier.uri | https://pedsnet.org/metadata/handle/20.500.14642/411 |
dc.provenance | Treatment of Henoch-Schonlein purpura (HSP) Nephritis |
dc.publisher | PEDSnet |
dc.relation.isreferencedby | Stone HK, Mitsnefes M, Dickinson K, et al. 2023. "Clinical course and management of children with IgA vasculitis with nephritis." _Pediatr Nephrol_ 38, 3721�3733. <br>DOI: [10.1007/s00467-023-06023-8](https://doi.org/10.1007/s00467-023-06023-8) |
dc.rights | a CC-BY Attribution 4.0 License. |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ |
dc.subject | Concept Set Development::Content Data Model::PEDSnet Data Model |
dc.subject | Concept Set Development::Concept Set Evaluation::Clinician Reviewed |
dc.subject | Concept Set Development::Concept Set Development Strategy::Broad |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Brand Pack Name |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Branded Drug |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Clinical Drug |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Branded Drug Form |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Clinical Drug Form |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Branded Drug Component |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Clinical Drug Component |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Multiple Ingredients |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Precise Ingredient |
dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Ingredient |
dc.subject.mesh | Angiotensin Converting Enzyme Inhibitor |
dc.subject.mesh | Thiazide Diuretic |
dc.subject.mesh | Calcium Channel Blocker |
dc.subject.other | RxNorm |
dc.subject.other | RxNorm Extension |
dc.title | Antihypertensive Medications |
dspace.entity.type | ConceptSet |
local.quality.status | Needs Refinement |
local.subject.flat | PEDSnet Data Model |
local.subject.flat | Clinician Reviewed |
local.subject.flat | Broad |
local.subject.flat | Brand Pack Name |
local.subject.flat | Semantic Branded Drug |
local.subject.flat | Semantic Clinical Drug |
local.subject.flat | Semantic Branded Drug Form |
local.subject.flat | Semantic Clinical Drug Form |
local.subject.flat | Semantic Branded Drug Component |
local.subject.flat | Semantic Clinical Drug Component |
local.subject.flat | Multiple Ingredients |
local.subject.flat | Precise Ingredient |
local.subject.flat | Ingredient |
relation.isStudyOfConceptSet | 9e8d04a8-d5be-4bd8-a904-c533a7dcd490 |
relation.isStudyOfConceptSet.latestForDiscovery | 9e8d04a8-d5be-4bd8-a904-c533a7dcd490 |
Files
Original bundle
1 - 1 of 1